



UNIVERSITÀ  
DEGLI STUDI  
FIRENZE

## FLORE

# Repository istituzionale dell'Università degli Studi di Firenze

### **Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses**

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

*Original Citation:*

Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses / Climent, Núria; García, Isabel; Marradi, Marco; Chiodo, Fabrizio; Miralles, Laia; Maleno, María José; Gatell, José María; García, Felipe; Penadés, Soledad; Plana, Montserrat. - In: NANOMEDICINE. - ISSN 1549-9634. - ELETTRONICO. - 14:(2018), pp. 339-351. [10.1016/j.nano.2017.11.009]

*Availability:*

This version is available at: 2158/1157147 since: 2021-03-28T11:46:17Z

*Published version:*

DOI: 10.1016/j.nano.2017.11.009

*Terms of use:*

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

*Publisher copyright claim:*

(Article begins on next page)

## Accepted Manuscript


Loading Dendritic Cells with Gold Nanoparticles (GNPs) Bearing HIV-Peptides and Mannosides Enhance HIV-Specific T Cell Responses

Núria Climent, Isabel García, Marco Marradi, Fabrizio Chiodo, Laia Miralles, María José Maleno, José María Gatell, Felipe García, Soledad Penadés, Montserrat Plana

PII: S1549-9634(17)30204-6  
DOI: doi: [10.1016/j.nano.2017.11.009](https://doi.org/10.1016/j.nano.2017.11.009)  
Reference: NANO 1694

To appear in: *Nanomedicine: Nanotechnology, Biology, and Medicine*

Received date: 11 July 2017  
Revised date: 5 October 2017  
Accepted date: 3 November 2017



Please cite this article as: Climent Núria, García Isabel, Marradi Marco, Chiodo Fabrizio, Miralles Laia, Maleno María José, Gatell José María, García Felipe, Penadés Soledad, Plana Montserrat, Loading Dendritic Cells with Gold Nanoparticles (GNPs) Bearing HIV-Peptides and Mannosides Enhance HIV-Specific T Cell Responses, *Nanomedicine: Nanotechnology, Biology, and Medicine* (2017), doi: [10.1016/j.nano.2017.11.009](https://doi.org/10.1016/j.nano.2017.11.009)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

***Loading Dendritic Cells with Gold Nanoparticles (GNPs) Bearing HIV-  
Peptides and Mannosides Enhance HIV-Specific T Cell Responses***

Authors: Núria Climent<sup>1</sup>, Isabel García<sup>2,3</sup>, Marco Marradi<sup>2,3</sup>, Fabrizio Chiodo<sup>3,4</sup>, Laia Miralles<sup>1</sup>, María José Maleno<sup>1</sup>, José María Gatell<sup>1,5</sup>, Felipe García<sup>1,5</sup>, Soledad Penadés<sup>2,3</sup>, Montserrat Plana<sup>1\*</sup>

<sup>1</sup> *AIDS Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clínic de Barcelona, Faculty of Medicine, University of Barcelona, Barcelona, Spain.*

<sup>2</sup> *Biomedical Research Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Paseo Miramón 182, 20014 Donostia-San Sebastián, Spain.*

<sup>3</sup> *CIC biomaGUNE, Paseo de Miramón 182, 20014 Donostia-San Sebastián, Spain.*

<sup>4</sup> *Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, The Netherland.*

<sup>5</sup> *Service of Infectious Diseases & AIDS Unit, Hospital Clínic de Barcelona, Faculty of Medicine, University of Barcelona, Barcelona, Spain.*

Corresponding author:

Dr. Montserrat Plana

IDIBAPS-Hospital Clínic Barcelona,

AIDS Research Group, Casanovas 143,

Barcelona 08036, Spain.

Tel: +34 93 2275400 ext.2884;

fax: +34 932271775;

e-mail: mplana@clinic.ub.es

**Word count for abstract:** 150

**Complete manuscript word count:** 5556

**Number of References:** 69

**Number of figures:** 6

**Number of tables:** 0

**Number of Supplementary online-only files:** 1

**Conflicts of interests:** The authors have declared that no competing interest exists.

**Organizations that funded your research:** This study was partially supported by grants: FIS PI12/00969, PI15/00480 and PI15/00641, from Plan Nacional de I+D and co-financed by ISCIII-Subdirección General de Evaluación and Fondo Europeo de

Desarrollo, Regional (FEDER) RD16/0025/0002, SAF2013-45232-R, SAF2015-66193-R, RIS, and HIVACAT.

\*RIS: Red Temática Cooperativa de Grupos de Investigación en Sida del Fondo de Investigación Sanitaria (FIS).

\*\*HIVACAT: HIV Vaccine Development Program in Catalonia.

\*\*\*IDIBAPS: Institut d'Investigacions Biomèdiques August Pi i Sunyer

**Prior presentation of abstracts at meetings:** An abstract regarding this research entitled "Loading Dendritic Cells with Gold Nanoparticles (GNPs) Bearing HIV-peptides and Mannosides Enhance HIV-specific T Cell Responses" has been presented at "HIV Research for Prevention 2016, Chicago, United States, October 17 - 21, 2016".

## ABSTRACT

Gold nanoparticles (GNPs) decorated with glycans ameliorate dendritic cells (DC) uptake, antigen-presentation and T-cells cross-talk, which are important aspects in vaccine design. GNPs allow for high antigen loading, DC targeting, lack of toxicity and are straightforward prepared and easy to handle. The present study aimed to assess the capacity of DC to process and present HIV-1-peptides loaded onto GNPs bearing high-mannoside-type oligosaccharides (P1@HM) to autologous T-cells from HIV-1 patients. The results showed that P1@HM increased HIV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell proliferation and induced highly functional cytokine secretion compared with HIV-peptides alone. P1@HM elicits a highly efficient secretion of pro-T<sub>H</sub>1 cytokines and chemokines, a moderate production of pro-T<sub>H</sub>2 and significant higher secretion of pro-inflammatory cytokines such as TNF $\alpha$  and IL-1 $\beta$ . Thus, co-delivery of HIV-1 antigens

and HM by GNPs is an excellent vaccine delivery system inducing HIV-specific cellular immune responses in HIV+ patients, being a promising approach to improve anti-HIV-1 vaccines.

**KEYWORDS:** Vaccine, gold nanoparticles (GNPs), HIV-1, CMV, high-mannoside-type oligosaccharides, cellular immunity.

### Abbreviations

AIDS: acquired immune deficiency syndrome; CFSE: Carboxyfluorescein Diacetate Succinimidyl Ester; CMV: Cytomegalovirus; CTL: Cytolytic T Lymphocyte; DC-SIGN: Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin; EDTA: Ethylenediaminetetraacetic acid; HIV: Human immunodeficiency virus; HLA: Human leukocyte antigens; IL-: Interleukin-; MHC: Major histocompatibility complex; MVA: Modified vaccinia Ankara; OVA: Ovalbumin; PGE<sub>2</sub>: Prostaglandin E<sub>2</sub>; SEA: Staphylococcus aureus enterotoxin A; SIV: Simian immunodeficiency virus; T<sub>H</sub>1 and T<sub>H</sub>2: T helper 1 and 2; TF: Thomsen–Friedenreich antigen; HM: high-mannosides derivatives; P1: KKWK-SLYNTVATL (HIV Gag p17) peptide

## 1. Background

The present paradigm for an optimal HIV-1 vaccine is to develop immunogens and vaccination protocols that permit the stimulation of a robust mucosal and systemic immunity, comprising both helper and cytotoxic T-lymphocyte mediated responses, in order to act at infection sites <sup>1</sup>. Until now, preventive and therapeutic vaccines strategies have been investigated against HIV. Preventive HIV vaccines are designed to protect from acquisition of HIV-infection, while therapeutic HIV vaccines are developed to control and eliminate the virus in order to achieve a ‘functional cure’ in individuals who have previously been infected by HIV <sup>2-5</sup>.

Dendritic cells (DC) are potent antigen presenting cells (APC) widely spread in the mucosal tissues and play a critical role in the initiation and control of protective immune responses against pathogens <sup>6</sup>. For this reason, targeting DC or, particularly, monocyte-derived dendritic cells (MDDCs) with selected antigens is a widely accepted strategy to induce and potentiate antigen-specific T-cell responses and an effective protective immunity <sup>7-11</sup>. The use of MDDCs is reinforced by recent findings that show how DC can be generated *in vivo* from monocytes in tissues under inflammatory conditions <sup>12,13</sup>. Accordingly, our group is testing at both clinical and non-clinical levels different therapeutic HIV-1 vaccines based on the use of MDDC and different immunogens such as heat-inactivated HIV-1 <sup>8</sup> and MVA vectors <sup>14</sup> with promising results.

Recent studies suggested that nanotechnology could play a pivotal role in HIV-1 therapeutics and vaccine design <sup>5,7,10,15-21</sup>. Nanoparticles have been proposed as new carriers to ameliorate DC antigen loading, which is important in DC-based vaccine

approaches<sup>5,10</sup>. Modified Gold nanorods promote cellular and humoral immunity, through activating APC compared to naked HIV envelope plasmid DNA treatment *in vivo*<sup>22</sup>. Gold nanoparticles decorated with antigenic carbohydrate ligands have been validated as potential prophylactic vaccine candidates against *Streptococcus pneumoniae*<sup>23,24</sup> and *Burkholderia mallei*<sup>25</sup>. Brilliant examples related to GNPs loaded with multiples copies of tumor associated TF carbohydrate antigen have been reported as potential anti-cancer vaccines<sup>26,27</sup>. The success of these nanoplatforms stems from their dispersion in water, resistance to enzymatic degradations, biocompatibility and ability to incorporate different ligands<sup>28</sup>. Current knowledge suggests that a primary vaccination (inducing humoral and CD4+ T-cell immune responses) combined by a subsequent boost with agents inducing CD8+ T- cell immune responses provides the most efficient response with the elicitation of both cellular and humoral immune responses<sup>29,30</sup>.

The C-type lectin called Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) constitute a major receptor for HIV-1 in dendritic cells<sup>31</sup>. DC-SIGN recognizes *N*-linked high-mannose glycan clusters on HIV gp120<sup>32,33</sup>. Consequently, mimicking the cluster presentation of oligomannosides from the virus surface is a strategic approach not only for carbohydrate-based antiviral compounds<sup>34</sup> but also for targeting antigens to DC<sup>35</sup>. Glycan-coated dendrimers and liposomes loading ovalbumin (OVA) peptides have been described to enhance antigen presentation in human DC. It has been shown that modification of liposome and dendrimers modification with the DC-SIGN-binding glycans induce efficient MHC Class I and MHC Class II presentation to CD8+ and CD4+ T cells, respectively<sup>36</sup>. DC-SIGN targeting strategies have also been studied in the design of anticancer vaccines<sup>37</sup>. In the field of HIV, gold nanoparticles presenting multiple copies of structural motifs of



the *N*-linked high-mannose glycan (manno GNPs) are effective inhibitors of DC-SIGN-mediated trans-infection of human T cells<sup>38</sup>. Furthermore, manno GNPs are captured by immature MDCC without inducing DC maturation in a DC-SIGN-dependent and -independent manner and part of them are co-localized with DC-SIGN in early endosomes<sup>39</sup>.

HIV-peptides corresponding to the sequence of HIV Gag epitopes have been previously described as highly immunogenic and able of inducing cytolytic T lymphocyte (CTL) response<sup>40,41</sup>. However, soluble peptides alone may not be an efficient platform for HIV vaccines because they are not as immunogenic as those which are co-delivered with other vehicles or adjuvants<sup>40</sup>. Multiple copies of these antigens on the surface of nanoparticles could induce robust immune responses.

In this context, we hypothesized that GNPs bearing both high-mannosides (HM) derivatives and selected HIV peptides potentiated with pro-inflammatory cytokines could be an improved design to enhance antigen capture by stimulating DC presentation able to break the immunotolerance promoted by high-mannose type glycans<sup>42</sup>. Such engineered compounds could induce effective HIV specific T cell immune responses. Due to that neither animal model perfectly recapitulates HIV infection in humans<sup>43</sup>, a good approach to validate such engineered compounds as prophylactic or therapeutic vaccines is to work *ex vivo* with freshly isolated human MDCCs and human T cells from HIV-infected patients, which represent the natural targets cells of HIV infection<sup>43</sup>. This *ex vivo* model is considered a more realistic scenario to support the efficacy of therapeutic vaccines (where HIV could have influenced on MDCC biology), in comparison with other models using MDCC from healthy volunteers<sup>44,45</sup>. We therefore assessed *ex vivo* the interaction of GNPs bearing a dimannoside conjugate and peptides

with MDDCs of HIV-1 infected patients and the capacity of MDDC to process and present the HIV-1 antigens to autologous human T-cells.

## 2. Material and methods

### 2.1 Ethics statement

This study received the approval of the Committee of Ethics and Clinical Investigation of the Hospital Clinic Universitari (Barcelona, Spain). All the subjects participating in the study were recruited at the Service of Infectious Diseases & AIDS Unit of this Hospital and gave their informed written consent.

### 2.2 Study individuals

Samples of EDTA-anticoagulated venous blood samples were obtained from 9 chronic asymptomatic HIV-1-infected patients HLA A\*0201 positives with baseline CD4<sup>+</sup> T cell counts >450 cells/mm<sup>3</sup>, and plasma viral load <50 HIV-1 RNA copies/ml who were on antiretroviral therapy.

### 2.3 Reagents

Peptides of HIV and CMV epitopes of Gagp17 and pp65 proteins respectively were supplied by Gene Script. Peptide sequences are: KKWK-SLYNTVATL (p17<sub>77-85</sub> HLA A\*0201) and KKWK-NLVPMVATV (CMV pp65<sub>495-503</sub> HLA A\*0201). All chemicals were purchased as reagent grade from Sigma-Aldrich unless otherwise stated and were used without further purification (Supplementary methods).

### Preparation of dimannose and glucose GNPs

For the preparation of HIV Gag p17 and CMV pp65 functionalized GNPs, gold glyconanoparticles carrying approximately 50% glucose or 50% dimannose (Man $\alpha$ 1-2Man) and 50% of a carboxylated linker were prepared by reduction in situ of Au(III) salt with sodium borohydride in the presence of the ligands, as described<sup>34,46-48</sup>.

Glucose, dimannose and carboxylated linker were derivatised with thiol-terminated linkers as previously reported<sup>34</sup> for binding onto gold nanoparticles core (Figure 2). 5-Mercaptopentyl-D-glucofuranoside (GlcC<sub>5</sub>SH), dimannoside and carboxylic acid-containing ligand were used as thiol-ending ligands and prepared as previously reported<sup>34</sup>.

Briefly, an aqueous solution of tetrachloroauric (Strem Chemicals) (0.025 M, 1 eq.) was added to a solution of a mixture of appropriate thiol ending ligands (0.012 M, 6 eq.) in MeOH/H<sub>2</sub>O/CH<sub>3</sub>COOH (3:3:1). An aqueous solution of NaBH<sub>4</sub> (1 M, 22 eq.) was then slowly added and the mixture was stirred for 2 hours at 25 °C. The solvent was subsequently evaporated at reduced pressure and the residue was washed with ethanol, re-dissolved in the minimum quantity of milliQ water, loaded into 5-10 cm segments of SnakeSkin® pleated dialysis tubing (Pierce, 3500 MWCO) and purified by dialysis against distilled water (3 l of water, recharging with fresh water every 6 hours over the course of 72 hours). The nanoparticles were obtained as brown powder after lyophilization (Supplementary methods).

### 2.5 Preparation of co-formulated GNPs including HIV-1- or CMV-peptides and dimannose

For the preparation of HIV Gag p17 and CMV pp65 functionalized GNPs, the previously prepared GNPs (GNP1 and GNP2) were coupled to KKWK tagged HIV Gag

p17 (P1) and CMV pp65 (P2) peptides (Gene Script) through a peptidic bond between the carboxylic group of the GNP1 and GNP2 and the amine group of the lysine present in the tagged peptide. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, 100  $\mu$ l, 19 mg/ml) and sulfo-*N*-hydroxysuccinimide (sulfo-NHS, 100  $\mu$ l, 43 mg/ml) were added to 60  $\mu$ l of GNPs solution (sodium borate buffer, pH=9.2; 0.01 M ClNa at 4 mg/ml). The mixtures were left under shaking 1 h and a solution of P1 and P2 peptides (415  $\mu$ l, 2 mg/ml in borate buffer) was added. Coupling reactions were left under shaking 24 h at RT. HIV Gag p17 (P1@glc and P1@HM) and CMV pp65 (P1@glc and P2@HM) GNPs were filtered and washed with HCl (5 mM) and H<sub>2</sub>O on Amicon filters (10 KDa MWCO) until no peptide was detected by Bradford analysis and were finally dialyzed (Snakeskin, cut-off 3000 Dalton).

## 2.6 Characterization of co-formulated GNPs

After coupling, the presence of HIV-Gag p17 and CMV pp65 onto the GNPs were assessed by <sup>1</sup>H-NMR. GNPs were also characterized by transmission electron microscopy (TEM) to determinate the average gold diameter. 2.7 Generation of MDDCs

The immunophenotype of immature MDDCs (imMDDCs) derived from 9 HIV-1 individuals using a well-established method<sup>14</sup> using IL-4 and GM-CSF both at a concentration of 1000 IU/ml was: CD86+, CD11c+, CD40+ and HLA-DR+. The purity of imMDDCs obtained was higher than 95% (Supplementary methods).

### **2.8 Pulsing of MDDCs with GNP's and maturation induction**

MDDCs were incubated for 48 h with GNP compounds containing 10 µg/ml of each peptide or with Gag p17 HIV or CMV pp65 peptides alone at 10 µg/ml each or with the HIV p24 antigen at 5 µg/ml and SEA as positive control of activation. To obtain mature MDDCs (mMDDCs), a maturation cocktail of recombinant human cytokines containing TNF- $\alpha$ , IL-6 (1000 IU/ml each, Strathmann Biotec AG), IL-1 $\beta$  (300 UI/ml, Strathmann Biotec AG) and PGE<sub>2</sub> (1 µg/ml, Pfizer, Madrid, Spain) was added at 2 h post-pulsing, and the mixture was incubated for a whole period of 48 h. Where indicated, pulsed MDDCs were not treated with the maturation cocktail.

### **2.9 Co-cultures of pulsed MDDCs with autologous lymphocytes: proliferation.**

As a source of enriched T cells, we used 9 samples of fresh PBMCs depleted of monocytes after plastic adherence, as indicated above for the generation of MDDCs. These monocyte-depleted lymphocytes were washed (3 $\times$ ) and re-suspended in serum-free XVIVO-10 medium and labelled with CFSE in order to analyse proliferation following the instructions of the manufacturer (CellTrace CFSE cell proliferation kit, Molecular Probes, Paisley, UK). Autologous matured MDDCs ( $6 \times 10^4$  MDDC/well) were washed (4 $\times$ ) and re-suspended in XVIVO-10 and co-cultured with autologous fresh CFSE-labelled lymphocytes ( $2 \times 10^5$  T-lymphocytes/well) in a final volume of 200 µL in XVIVO-10 medium supplemented with 1 mM zidovudine to avoid possible replication of endogenous HIV-1. The contribution of MDDCs and monocyte depleted PBMCs (lymphocytes) alone were determined as negative controls of proliferation.

The co-cultures were done in triplicates at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. After 6–7 days, proliferating CD4<sup>+</sup> (CD3<sup>+</sup> CD8<sup>-</sup>) and CD8<sup>+</sup> (CD3<sup>+</sup> CD8<sup>+</sup>)

T cells were determined by direct staining with monoclonal Abs (mAbs) conjugated with  $\alpha$ -CD3-Per-CP and  $\alpha$ -CD8-PE. Mouse immunoglobulin (Ig) isotypes mAbs (from BD Biosciences) of unknown antigen specificity conjugated with PerCP or PE were used as negative control mAbs. The stained cells were analysed on a FACS Calibur flow cytometer (BD Biosciences). T cell populations were selected by forward and side light-scatter parameters and sub-gated for CD8- or CD8+ expression. Cells that proliferated after the co-culture had lower intensity of CFSE (CFSE<sup>low</sup>) in comparison with basal conditions. Proliferation was expressed as the percentage of CFSE<sup>low</sup> cells after 6 days of co-culture.

### **2.10 Co-cultures of pulsed MDDCs with autologous lymphocytes: cytokine expression**

In addition, the co-culture supernatants were collected after 6 days and stored at  $-80^{\circ}\text{C}$  for further cytokine quantification of 25 cytokines<sup>14</sup> (supplementary information).

### **2.11 Statistical analysis**

Data were analysed using the GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Comparisons between two groups were performed by paired parametric test (Student's *t*-tests) depending on normal distribution (Kolmogorov–Smirnov normality test). Non-parametric paired values were analysed by Wilcoxon signed rank test. For unpaired or paired non-parametric multiple comparisons Kruskal–Wallis test or Friedman's test both followed by Dunn's post-test was used, respectively. For all tests used, two sided *p*-values  $<0.05$  were considered to indicate statistical significance.

### 3. Results

#### 3.1 Preparation of GNPs bearing the HIV Gag p17 and CMV pp65 immunogenic peptides and mannosides or glucosides

In this work we have loaded gold nanoparticles (GNPs) with HIV-peptides or CMV-peptides and mannosides and challenged them through *ex vivo* assays with monocyte derived dendritic cells (MDDCs) and autologous lymphocytes from HIV+-infected patients in search for specific T cell responses (Figure 1A).

GNPs compound were prepared using a well-established methodology. Briefly, KKWK tagged P1 and P2 HLA-A\*0201-restricted peptides, from HIV and CMV, respectively (Figure 1B) were covalently linked to GNP1 and GNP2 by amide chemistry and were characterized by TEM (Figure 1C and Figure 1D).

Precursors GNPs (GNP1 and GNP2) were obtained by reduction of an aqueous solution (0.025 M, 1 eq.) of tetrachloroauric Au(III) with NaBH<sub>4</sub> in the presence of an excess of a mixture of the corresponding thiol-derivatized glucose or dimannose saccharides and carboxylic acid-containing molecules (Figure 2 and Figure S1). After purification by dialysis, the GNPs were characterized by <sup>1</sup>H NMR spectroscopy and transmission electron microscopy (TEM) (Figure S2-S4). The amino group of lysines located on the KKWK sequence react with gold nanoparticles (GNP1 and GNP2 in Figure 2 and Figure S5) previously activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-sulfo-hydroxysuccinimide (sulfo-NHS). After coupling, all P1@glc, P1@HM, P2@glc and P2@HM GNPs were characterized by <sup>1</sup>H NMR to check the presence of HIV-Gagp17 and CMV pp65 peptides on GNPs (Figure S6-S9). The <sup>1</sup>H-NMR of conjugates show a broad signal between 0.7-0.9 ppm

indicating the presence of peptides on the GNP (*CH3* of leucine residues). Less intense signals related to the peptides were also detected around 3 ppm and between 6.8-7.4 ppm (aromatic region). Water solutions of GNPs bearing the HIV Gagp17 and CMV pp65 immunogenic peptides and mannosides were stable for weeks. In addition, TEM micrographs showed no aggregations and uniform particle size (Figure 1D, and Figure S10-12). The mean diameter of the GNPs was determined to be 2.3nm (SD = 0.7 nm) for HIV Gagp17@manno GNPs and 1.6 nm (SD = 0.6nm) for CMV pp65@manno GNPs (Figure S11). Soluble free peptides, GNPs (GNP1 and GNP2), P1@glc and P2@glc GNPs were synthesized as comparative compounds. Zeta potential measurements (Figure S13 and S14) and UV-Vis scan were also determined of all GNPs (Figure S15).

### **3.2 T-cell proliferation induced by autologous MDDC pulsed with GNPs bearing the HIV Gag p17 and CMV pp65 immunogenic peptides**

To determine the capacity of GNPs carrying the HIV Gag p17 peptide (P1) or the CMV pp65 peptide (P2) specific for HLA-A\*02 and mannosides (HM) with the addition or without adding a maturation cocktail of cytokines to promote antigen specific T cell proliferation, the interaction of GNPs with MDDCs from 9 HIV+ patients in triplicates and their potency to induce subsequent stimulation of autologous T cells was studied.

Analysis and results of T cell proliferation of a representative individual is shown when maturation cocktail was added after the pulsing of MDDC (Figure 3A). In terms of T cell proliferation, HIV Gagp17@manno GNPs (P1@HM) induced a



significant better CD8<sup>+</sup> T cells response than negative control or manno GNPs or soluble peptide P1 or P1@glc or even recombinant soluble HIV Gag p24 antigen, reaching statistical significance in all cases ( $p < 0.05$ ) (Figure 3B). Similarly, a better response was obtained by CMV pp65@manno GNPs (P2@HM), the compound bearing CMV peptide and mannosides, than the compounds without HM, such as the soluble peptide (P2) or the CMV pp65@glucose GNPs (P2@glc) ( $p = 0.0992$  and  $p < 0.05$ , respectively, Figure 3B).

In addition, the proliferation of CD4<sup>+</sup> T cells using HIV Gagp17@manno GNPs (P1@HM) had a tendency ( $p < 0.1$ ) to be higher than the induced by manno GNPs (GNP2), soluble peptide P1 or soluble recombinant HIV Gag p24 antigen (Figure 3C). In accordance with these results, an increased proliferation was induced by CMV pp65@manno GNPs (P2@HM) than by the soluble peptide P2 ( $p < 0.05$ , Figure 3C).

Furthermore, GNP2 without peptide coating was unable to increase either CD8<sup>+</sup> or CD4<sup>+</sup> T cell proliferation (Figure 3B-C).

Surprisingly, the proliferation induced by the P1@HM was higher than the induced by whole HIV Gag p24 antigen (Figure 3B-C). In contrast, no increase of proliferation was found when any maturation agent was added after the pulsing of MDDCs with P1@HM or P2@HM GNPs (Figure 3D-E).

### **3.3 HIV Gagp17@manno GNPs increased the secretion of pro-T<sub>H</sub>1 cytokines and chemokines**

To determine the capacity of GNPs carrying HM and the P1 or P2 to promote cytokine secretion, the interaction of each batch of P1@HM and P2@HM with MDDCs from HIV<sup>+</sup> patients, after the addition of maturation cocktail was studied in the co-cultures from 9 HIV-1 patients in duplicates.

P1@HM significantly increased more than 3-folds the secretion of pro-T<sub>H</sub>1 cytokines including IFN- $\gamma$ , IL-2R, IL-12 and IL-15 comparing with the soluble peptides ( $p < 0.01$ ). Similarly, P2@HM also promote the mentioned T<sub>H</sub>1 cytokines comparing with the soluble peptides, ( $p < 0.05$ ,  $p < 0.1$ ,  $p < 0.01$ , and  $p < 0.01$ , respectively, Figure 4A) and with P2@glc ( $p < 0.05$ ,  $p < 0.01$ ,  $p < 0.01$ , and  $p < 0.01$ , respectively, Figure 4A). The T<sub>H</sub>1 chemokines MIP-1 $\alpha$  (CCL3), MIP-1 $\beta$  (CCL4), CCL5 (RANTES), MIG and IP-10 also increase with P1@HM compared with the corresponding soluble peptides ( $p < 0.05$ , Figure 4B).

Accordingly to the proliferation results, P1@HM also induced a higher T<sub>H</sub>1 cytokine and chemokine profile (IL2-R, IL-12, MIP-1 $\alpha$  (CCL4),  $p < 0.05$ ) than soluble recombinant HIV Gag p24 antigen, suggesting that a unique peptide bound to manno GNPs could have a better immunogenic capacity.

Likewise, P2@HM also promote the mentioned cytokines profile of P1@HM comparing with the soluble peptides ( $p < 0.05$ , Figure 4B), but the highest secretion of MIG and IP-10 by P2@HM reaches only significance when compared to P2@glc ( $p < 0.01$ , Figure 4 B).

### **3.4 HIV Gagp17@manno GNPs increased the secretion of some pro-T<sub>H</sub>2 cytokines**

The secreted pro-T<sub>H</sub>2 cytokines were also quantified in the co-cultures of GNPs-pulsed-MDDC, after the addition of a maturation cocktail, with autologous T cells from HIV+ patients.

Both P1@HM and P2@HM significantly increased more than 2 folds the secretion of pro-T<sub>H</sub>2 cytokines such as IL-13, IL-5 and Eotaxin, however no significant differences were found for two pro-T<sub>H</sub>2 cytokines such as IL-4, MCP-1 and IL-6 compared with the peptide alone (Figure 5). Only a trend to a higher increase of IL-4

was found between P1@HM and the peptide alone (Figure 5). Concerning the P2@HM compared with P2@glc, a rise was found in IL-4, and IL-6 secretion ( $p < 0.01$ ). Nevertheless, both P1@HM and P2@HM induced higher levels of IL-4, MCP-1 and IL-6 than GNP2 ( $p < 0.01$ ,  $p < 0.05$  and  $p < 0.01$ , respectively).

### **3.5 HIV Gagp17@manno GNPs increased the secretion of pro-inflammatory cytokines**

The pro-inflammatory cytokine secretion was also quantified in the co-cultures of MDDCs, after the addition of a maturation cocktail, with autologous T cells from HIV+ patients.

The pro-inflammatory cytokines TNF $\alpha$ , IL-1 $\beta$ , IL-8, GM-CSF, and IL-17 also increase with P1@HM compared with the corresponding soluble peptides ( $p < 0.05$ , Figure 6). In contrast, IL1-RA, which is an anti-inflammatory protein, inhibiting IL-1 $\beta$  signalling, was decreased not only by P1@HM but also by any treatment compared to the negative control ( $p < 0.01$ , Figure 6).

No significant differences were found between the secretion of IFN- $\alpha$ , IL-7 and IL-10, which is associated with suppressive responses, induced by P1@HM compounds compared with the controls (data not shown).

Likewise, CMV pp65@manno GNPs (P2@HM) also promote pro-inflammatory cytokines comparing with the soluble peptides P2 ( $p < 0.05$ , Figure 6). Furthermore, GNP2, without any peptide coating, were able to enhance IL-12, IL-15 ( $p < 0.01$  and  $p < 0.05$ , respectively, Figure 4A), MIG and TNF $\alpha$  ( $p < 0.01$ , Figure 4B and  $p = 0.0578$ , Figure 6, respectively). In contrast, the amount of pro-T<sub>H</sub>2 cytokines such as IL-6 and MCP-1 (CCL2) and the anti-inflammatory cytokine IL1-RA were decreased with GNP2

compared with negative control ( $p=0.0322$  and  $p<0.005$  and  $p<0.005$  respectively, Figure 5 and 6).

These results indicate the potency of the mannosides covalently linked to GNPs able to induce cytokines and chemokines as important immune factors that potentiate higher immune responses.

#### 4. Discussion

We found that MDDCs pulsed with nanoparticles P1@HM or P2@HM exhibit enhanced capacities in stimulating virus antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T-cell proliferation. These results suggest that co-delivery of high mannose ligands (HM) with the HIV peptides antigen coated on GNPs has an enhanced adjuvant effect, inducing strong T cell proliferative responses following *ex vivo* pulsing and after full maturation of autologous DC, whereas no addition of maturation agents or GNPs without P1 or P2 peptides fail to do so. The enhancement of T-cell proliferation by P1@HM or P2@HM is in agreement with the results of a previous work, where we observed an increased MDDC-capture of GNPs containing HM, which is mediated by both DC-SIGN-dependent and -independent pathways and suggesting that a higher antigen capture could induce higher immunoresponses<sup>39</sup>. Although it appears that the stimulatory effect of P1@HM on CD4 T cell proliferation is less significant than that of CD8 T cell proliferation, in both cases the proliferation was higher than the p24 alone, suggesting that P1@HM had an adjuvant effect induced by HM incorporation to the GNPs. Vaccines based on HM conjugates are advantageous, because they may also target the C-type lectins (such as DC-SIGN) expressed by both macrophages and DCs and thus facilitate antigen capture and presentation<sup>49-52</sup>. Internalization of GNPs mediated by C-type lectin-like receptors in to DC, including DC residing in peripheral lymph nodes, promote antigen presentation to T cells both in an *ex vivo* and in an *in vivo* mouse model

and there is a good association between both *in vivo* experiments and in *ex vivo* DC–T cell co-cultures<sup>53</sup>. Such results suggest that targeting DCs by HM could be a good approach for targeting not only DC *ex vivo* but also DC *in vivo*. Alternatively, it is possible that GNPs, in addition of being captured by specific C type lectin receptors and/or macropinocytosis<sup>52</sup> they could trigger complement activation, not only mediated by MBL but also by the nonspecific adsorption of particular complement protein on GNPs contributing to the phagocytosis of GNPs by human APC. Consequently, GNPs could enhance innate immunity and cellular up-take by a complement dependent mechanism which could potentiate immunological responses<sup>54</sup>.

In those second set of functional experiments with our *ex vivo* model, we also noted that P1@HM and P2@HM significantly increased the secretion of pro-T<sub>H</sub>1 cytokines, including IFN- $\gamma$ , IL-2R, IL-12 and IL-15, respect to free peptides. In addition, P2@HM significantly increased the secretion of pro-T<sub>H</sub>1 cytokines compared to P2@glc. These results are consistent with the proliferation responses and suggested that the GNPs containing both HM and peptide induced a higher T<sub>H</sub>1 immunoresponse suggesting that a higher antigen capture mediated by HM could induce higher immunoresponses<sup>39</sup>. IL-12 secretion from APC potentiates the differentiation of T<sub>H</sub>1 cells. We showed that all the compounds tested containing HM such as P1@HM, P2@HM and GNP2, after fully maturation, promoted high IL-12 secretion. In agreement with these results, alternative studies found that multifunctional NPs including both mannose and adjuvants have high cancer immunotherapeutic potential in terms of inducing an effective T<sub>H</sub>1 immune response<sup>55</sup>.

Moreover, it has been reported that HM alone are unable to induce maturation and secretion of pro-inflammatory cytokines by human MDDCs<sup>42</sup>. In accordance with

those results, no increase of proliferation was found when any maturation agent was added after the pulsing of MDDCs with P1@HM or P2@HM. As expected, maturing agents are required to process, present the antigens and mature MDDC in order to activate proliferative T cell responses. These results suggest that a secondary signal such as the addition of a pro-T<sub>H</sub>1 adjuvant as the maturation cocktail, which mimics a pro-inflammatory environment, is necessary to induce antigen presentation and full maturation. Consistent with our results, *in vivo* studies performed with compounds including mannose, antigen and adjuvants, demonstrated a superior pro-T<sub>H</sub>1 immune response than strategies lacking both the adjuvant or the mannose compound<sup>50,55</sup>.

Concerning the IL-15 up regulation, it has also been reported that IL-15 enhances effector memory CD8<sup>+</sup> T cells in primates immunized with a HIV-1 DNA vaccine, suggesting that this cytokine could be an adjuvant for HIV-1 vaccines<sup>56</sup>. The presence of HIV Gagp17@manno GNPs may produce the release of IL-15 that in turn could promote the expansion and survival of antigen-specific CD8<sup>+</sup> T cells<sup>57</sup>.

In addition, HIV Gagp17@manno GNPs also significantly increased the T<sub>H</sub>1 chemokine: the  $\beta$ -chemokines MIP-1 $\alpha$  (CCL3), MIP-1 $\beta$  (CCL4) and RANTES (CCL5), but also MIG (CXCL9) and IP-10 (CXCL10). These chemokines are also known to induce migration of cells to both mucosal and systemic sites and specially attract DCs, monocytes, NK cells, and activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells to sites of antigen processing to further mount the immune response<sup>58-60</sup>. The P1@HM-mediated increase on these  $\beta$ -chemokines is appropriate against HIV-1 infection since strong HIV-1 inhibition of R5 HIV-1 strains are related with these mediators<sup>61</sup>. Moreover, those chemokines contribute to initiate and expand antigen-specific mucosal immune responses through the activation of helper T cells, which enhance B cell responses and the function of APCs<sup>62</sup>.

Furthermore, manno GNPs (HM) without any coated peptide, were able to enhance the secretion of pro-T<sub>H</sub>1 mediators such as IL-12, IL-15, MIG and TNF $\alpha$  in the cocultures, suggesting that both HM coated on GNP and fully maturation, could polarize towards a T<sub>H</sub>1 response mediated by IL-12<sup>55,63</sup>. A more pronounced T<sub>H</sub>1 versus T<sub>H</sub>2 response is desired for successful control of HIV-1 infection<sup>64</sup>. Our findings suggest that P1@HM and P2@HM could play a role in polarization towards a T<sub>H</sub>1 response, as suggested by the increased release of pro-inflammatory/T<sub>H</sub>1 cytokines and chemokines observed in the presence of P1@HM.

Moreover, we found that HIV Gagp17@manno GNPs significantly increased the production of some pro-T<sub>H</sub>2 cytokines such as IL-13, IL-5<sup>65</sup> and Eotaxin<sup>66</sup>, though a weak amount of IL-4 was detected. T<sub>H</sub>2 cytokines are important in humoral immunity<sup>67</sup>. It has been reported that mannosylated compounds such as mannans induced a pattern of T<sub>H</sub>1/ T<sub>H</sub>2 cytokines including both IFN- $\gamma$  and IL-12, but also with IL-13 and some degree of IL-4 secreted by murine dendritic cells<sup>51</sup>. IFN- $\gamma$ , IL-2, and in a weak extent IL-4 and IL-5 were also produced by T cells in a murine model after immunization with OVA linked to HM compounds such as *O*-glycan oligomannoses when a potent adjuvant was added<sup>50</sup>. IL-10 is a T<sub>H</sub>2 cytokine secreted by DC that promote immunosuppression and has been increased with HM compounds from the HIV-1 gp120<sup>42</sup>. However, HIV Gagp17@manno GNPs under our conditions are unable to significantly increase IL-10, suggesting that P1@HM could not induce immunosuppression. This result coincides with our previous work where production of IL-10 was not enhanced by human MDDC exposed to manno GNPs<sup>39</sup> and results obtained by others showing that HM compound such as mannans did not induce IL-10 secretion by murine DC<sup>51</sup>.

It is noteworthy, that the amount of pro- $T_H2$  cytokines such as IL-6 and MCP-1 (CCL2) were decreased with manno GNPs alone compared to the negative control with medium alone. These results suggest that HM compounds on GNPs, when combined with a potent  $T_H1$  activation agent which induce fully maturation of DC such as a pro-inflammatory environment are able to stimulate a  $T_H1$  profile suitable, not only against HIV infection, but also against CMV.

Apart from  $T_H1$  cytokines, our results indicated that P1@HM also increased the secretion of the proinflammatory cytokines TNF- $\alpha$ , IL-1 $\beta$ , GM-CSF, and IL-17, however, consistently reduced the anti-inflammatory cytokine IL1-RA that antagonized IL-1 function. These results are in agreement with reports by other authors, who found that HM related compounds such as mannans stimulated murine DC to express TNF- $\alpha$ , IL-1 $\beta$ , and GM-CSF<sup>51</sup>. Nevertheless, our previous results suggest that HM compounds alone were not able to induce human MDDC maturation<sup>39</sup>. For that reason and in order to bypass this inconvenient, the DC were fully matured adding a pro- $T_H1$  maturation cocktail. As expected, addition of these maturing agents enhanced the co-stimulatory capacity of DC promoting DC maturation and a pro-inflammatory environment able to activate T cells. Accordingly, it has been reported that a high immune response was induced by immunization with OVA linked to oligomannose compounds when a potent pro  $T_H1$ -adjuvant named AbISCOH-100 was added<sup>50</sup>. Altogether, these results suggest that both a pro-inflammatory environment and a high capture of APC mediated by HM compounds are necessary to induce a potent antigen specific immune response.

Altogether, our results suggested that these formulations not only induce a  $T_H1$  response but also promote a combined  $T_H1/T_H2$  profile which could activate B cells enhancing the humoral arm of the immune system. We could speculate that our GNPs likely could induce not only cellular response but also antibodies against the loaded



antigens *in vivo*. In that scenario, the immunization with compounds containing HM epitopes and peptides could hypothetically induce not only a HIV-specific cellular immune response but also an antibody response, similar to that exerted by the broadly neutralizing 2G12 antibody<sup>15,68</sup> and could have an inherent capacity to block dendritic cell mediated HIV trans infection<sup>38,69</sup>.

Summarizing, HIV Gagp17@manno GNPs formulation enhanced antigen presentation by DC, able to activate a highly functional CD4+ and CD8+ T cells immune responses. Those formulations based on multifunctional GNPs could promote multiple arms of the immune system inducing a high adjuvant effect in an HIV vaccine context.

In this study, GNPs were used as a vaccine delivery system after functionalization with mannosides and HIV-1 or CMV virus-derived T-cell epitopes. This formulations resulted in increased T-cell mediated immune response even in chronically infected HIV-1 positive humans in an *ex vivo* model, providing a promising approach to the development of clinically useful anti-HIV or CMV prophylactic and therapeutic vaccination strategies.

## Acknowledgments

We appreciate the help of L. Liz-Marzan with nanoparticles analysis, advice and preparation of the paper, Cristina Rovira and Carmen Hurtado for their technical assistance in sample processing.

## Figure legends

**Figure 1. Schematic representation of the new *ex vivo* assays performed with formulations based on peptide conjugated GNPs.** (A) Schematic diagram of HIV-GNPs interaction, process and antigen presentation in APC (DC) to T cells (B) Schematic diagram of HIV Gag p17 and CMV pp65 peptides with a linker sequence KKWK used to manufacture the Peptide@manno GNPs. (C) Diagram of HIV Gagp17@manno GNPs bearing both mannose conjugate and the HIV Gag p17 immunogenic peptide SLYNTVATL (SL9), and CMV pp65@manno GNPs bearing both mannose conjugate and CMV pp65 peptide NLVPMVATV. (D) Characterization by Transmission Electron Microscopy (TEM) of GNPs.

**Figure 2. Gold nanoparticles prepared and used in this work and their synthetic strategy.** The starting GNPs have been functionalized with a glucose or a dimannose conjugate (GNP1 and GNP2) and a carboxylic acid-containing molecule as ligands. HIV-1 Gag p17 (P1) and CMV pp65 (P2) peptides were then introduced in a subsequent step by amide chemistry to obtain P1@glc, P1@HM, P2@glc and P2@HM GNPs.

**Figure 3. T-cell proliferation induced by autologous MDDC pulsed with Peptide@manno GNPs.** T cell proliferation in response to autologous MDDCs pulsed with P1, P1@glc, P1@HM P2, P2@glc, and P2@HM at a dose of 10 µg/ml of peptide and SEA as a positive control (1ng/ml) was assessed in co-cultures ( $n = 9$ ). MDDCs were also untreated (NC) and pulsed with GNP2 and soluble p24 at 5 µg/ml. (A) Density plots of gating and results of T cell proliferation of a representative individual is shown when maturation cocktail was added after the pulsing of MDDC. Cells were gated by CD3<sup>+</sup> lymphocytes and then CFSE<sup>low</sup> was quantified in CD8<sup>+</sup> T cells and

CD4<sup>+</sup> T cells (CD3<sup>+</sup> CD8<sup>-</sup>) by flow cytometry. Box and whisker plots of the percentage of proliferation from (B) CD8<sup>+</sup> T cells and (C) CD4<sup>+</sup> T cells by CFSE<sup>low</sup> are shown when maturation cocktail was added after the pulsing of MDDC (+). (D) CD8<sup>+</sup> T cells and (E) CD4<sup>+</sup> T cells by CFSE<sup>low</sup> are shown when any maturation cocktail was added after the pulsing of MDDC (-). Boxes represent interquartile ranges; the horizontal bar within each box is the median. Whiskers indicate the 10th and 90th percentiles. Wilcoxon signed rank test, \**P* < 0.05, \*\**P* < 0.01. GNP2: manno GNPs; NC: Negative Control; P1: HIV Gagp17; P1@glc: HIV Gagp17@glucose GNPs; P1@HM: HIV Gagp17@manno GNPs; P2: CMV pp65; P2@glc: CMV pp65@glucose GNPs; P2@HM: CMV pp65@manno GNPs; p24: HIV p24 antigen; SEA: Staphylococcus aureus enterotoxin A.

**Figure 4. Secretion of pro-T<sub>H</sub>1 cytokines and pro-T<sub>H</sub>1 chemokines by autologous MDDC pulsed with Peptide@manno GNPs.** Quantification by Cytokine Human 25-Plex Panel™ assay of cytokine secretion pattern from co-culture of MDDCs treated with P1, P1@HM, P2, P2@glc, and P2@HM at a dose of 10 µg/ml and p24 (5 µg/ml) with autologous T cells. The supernatants were collected and the concentrations of cytokines and chemokines were analysed (9 individuals in duplicates). (A) T<sub>H</sub>1 cytokines, (B) T<sub>H</sub>1 chemokines are shown. Boxes represent interquartile ranges; the horizontal bar within each box is the median. Whiskers indicate the 10th and 90th percentiles. Wilcoxon signed rank test, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.005.

**Figure 5. Secretion of pro-T<sub>H</sub>2 cytokines by autologous MDDC pulsed with Peptide@manno GNPs.** Quantification of cytokine secretion after co-culture of treated MDDCs with autologous T cells. The supernatants were collected and the

concentrations of cytokines and chemokines were analysed (9 individuals in duplicates). Th2 cytokines are shown: IL-13, IL-5, Eotaxin, IL-4, MCP-1 and IL-6. Wilcoxon signed rank test,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.005$ .

**Figure 6. Peptide@manno GNPs activate T cells and promote pro-inflammatory cytokine secretion.** Quantification of cytokine secretion after co-culture of treated MDDCs with autologous T cells. The supernatants were collected and the concentrations of cytokines and chemokines were analysed (9 individuals in duplicates). Pro-inflammatory cytokines are shown: TNF- $\alpha$ , IL-1- $\beta$ , IL-8, GM-CSF, IL-17 and the anti-inflammatory cytokine IL-1-RA. Wilcoxon signed rank test,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.005$ .

## References

1. Munier CML, Andersen CR, Kelleher AD. HIV vaccines: progress to date. *Drugs* 2011;**71**:387–414.
2. Gray GE, Laher F, Lazarus E, Ensoli B, Corey L. Approaches to preventative and therapeutic HIV vaccines. *Curr Opin Virol* 2016;**17**:104–9.
3. Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. *J Int AIDS Soc* 2015;**18**:20497.
4. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. *Nature* 1987;**327**:473–6.
5. Vacas-Córdoba E, Climent N, De La Mata FJ, Plana M, Gómez R, Pion M, *et al.* Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation. *Nanomed* 2014;**9**:2683–702.
6. Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. *Trends Immunol* 2007;**28**:227–33.
7. Climent N, Munier S, Piqué N, García F, Pavot V, Primard C, *et al.* Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. *Vaccine* 2014;**32**:6266–76.
8. García F, Climent N, Guardo AC, Gil C, León A, Autran B, *et al.* A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. *Sci Transl Med* 2013;**5**:166ra2.
9. García F, Plana M, Climent N, León A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: the way ahead. *Hum Vaccines Immunother* 2013;**9**:2445–52.
10. Pavot V, Climent N, Rochereau N, Garcia F, Genin C, Tiraby G, *et al.* Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. *Biomaterials* 2016;**75**:327–39.
11. Steinman RM. Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 2012;**30**:1–22.
12. Cheong C, Matos I, Choi J-H, Dandamudi DB, Shrestha E, Longhi MP, *et al.* Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. *Cell* 2010;**143**:416–29.
13. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. *Science* 2010;**327**:656–61.
14. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, *et al.* Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-

- specific CD8(+) T cell responses in HIV-1-infected individuals. *PLoS One* 2011;**6**:e19644.
15. Chiodo F, Enríquez-Navas PM, Angulo J, Marradi M, Penadés S. Assembling different antennas of the gp120 high mannose-type glycans on gold nanoparticles provides superior binding to the anti-HIV antibody 2G12 than the individual antennas. *Carbohydr Res* 2015;**405**:102–9.
  16. Neves J das, Amiji MM, Bahia MF, Sarmiento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. *Adv Drug Deliv Rev* 2010;**62**:458–77.
  17. Kumar R, Ray PC, Datta D, Bansal GP, Angov E, Kumar N. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. *Vaccine* 2015;**33**:5064–71.
  18. Qiao Y, Huang Y, Qiu C, Yue X, Deng L, Wan Y, *et al.* The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses. *Biomaterials* 2010;**31**:115–23.
  19. Rai M, Ingle AP, Birla S, Yadav A, Santos CAD. Strategic role of selected noble metal nanoparticles in medicine. *Crit Rev Microbiol* 2015;1–24.
  20. Liu Y, Chen C. Role of nanotechnology in HIV/AIDS vaccine development. *Adv Drug Deliv Rev* 2016;**103**:76–89.
  21. Carabineiro SAC. Applications of Gold Nanoparticles in Nanomedicine: Recent Advances in Vaccines. *Mol Basel Switz* 2017;**22**.
  22. Xu L, Liu Y, Chen Z, Li W, Liu Y, Wang L, *et al.* Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. *Nano Lett* 2012;**12**:2003–12.
  23. Safari D, Marradi M, Chiodo F, Th Dekker HA, Shan Y, Adamo R, *et al.* Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. *Nanomed* 2012;**7**:651–62.
  24. Vetro M, Safari D, Fallarini S, Salsabila K, Lahmann M, Penadés S, *et al.* Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model. *Nanomed* 2016;**12**:13–23.
  25. Gregory AE, Judy BM, Qazi O, Blumentritt CA, Brown KA, Shaw AM, *et al.* A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. *Nanomedicine Nanotechnol Biol Med* 2015;**11**:447–56.
  26. Brinãs RP, Sundgren A, Sahoo P, Morey S, Rittenhouse-Olson K, Wilding GE, *et al.* Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. *Bioconjug Chem* 2012;**23**:1513–23.

27. Parry AL, Clemson NA, Ellis J, Bernhard SSR, Davis BG, Cameron NR. 'Multicopy multivalent' glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines. *J Am Chem Soc* 2013;**135**:9362–5.
28. Marradi M, Chiodo F, García I, Penadés S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. *Chem Soc Rev* 2013;**42**:4728–45.
29. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. *Nat Rev Immunol* 2010;**10**:11–23.
30. Kim JH, Excler J-L, Michael NL. Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. *Annu Rev Med* 2015;**66**:423–37.
31. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, Clark G, *et al.* HIV gp120 receptors on human dendritic cells. *Blood* 2001;**98**:2482–8.
32. Drickamer K. Increasing diversity of animal lectin structures. *Curr Opin Struct Biol* 1995;**5**:612–6.
33. Lifson J, Coutré S, Huang E, Engleman E. Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. *J Exp Med* 1986;**164**:2101–6.
34. Martínez-Avila O, Hijazi K, Marradi M, Clavel C, Campion C, Kelly C, *et al.* Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. *Chem Weinh Bergstr Ger* 2009;**15**:9874–88.
35. Rieger J, Freichels H, Imberty A, Putaux J-L, Delair T, Jérôme C, *et al.* Polyester nanoparticles presenting mannose residues: toward the development of new vaccine delivery systems combining biodegradability and targeting properties. *Biomacromolecules* 2009;**10**:651–7.
36. Fehres CM, Kalay H, Bruijns SCM, Musaafir SAM, Ambrosini M, Bloois L van, *et al.* Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. *J Control Release Off J Control Release Soc* 2015;**203**:67–76.
37. García-Vallejo JJ, Unger WWJ, Kalay H, Kooyk Y van. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. *Oncoimmunology* 2013;**2**:e23040.
38. Martínez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcamí J, Penadés S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. *Chembiochem Eur J Chem Biol* 2009;**10**:1806–9.
39. Arnáiz B, Martínez-Ávila O, Falcon-Perez JM, Penadés S. Cellular uptake of gold nanoparticles bearing HIV gp120 oligomannosides. *Bioconjug Chem* 2012;**23**:814–25.

40. Ding Y, Liu J, Lu S, Igweze J, Xu W, Kuang D, *et al.* Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response. *J Control Release Off J Control Release Soc* 2016;**236**:22–30.
41. Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M, Bereta M. The HIV-1 HLA-A2-SLYNTVATL Is a Help-Independent CTL Epitope. *J Immunol* 2004;**172**:5249–61.
42. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SPN, Dionisio R, *et al.* HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. *PLoS Pathog* 2007;**3**:e169.
43. Nixon CC, Mavigner M, Silvestri G, Garcia JV. In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies. *J Infect Dis* 2017;**215**:S142–51.
44. Brandler S, Lepelley A, Desdouits M, Guivel-Benhassine F, Ceccaldi P-E, Lévy Y, *et al.* Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. *J Virol* 2010;**84**:5314–28.
45. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, *et al.* Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8+ T Cell Responses in HIV-1-Infected Individuals. *PLOS ONE* 2011;**6**:e19644.
46. He S, Garcia I, Gallo J, Penadés S. A step-heating procedure for the synthesis of high-quality FePt nanostars. *CrystEngComm* 2009;**11**:2605–7.
47. Patra HK, Banerjee S, Chaudhuri U, Lahiri P, Dasgupta AK. Cell selective response to gold nanoparticles. *Nanomedicine Nanotechnol Biol Med* 2007;**3**:111–9.
48. Marradi M, Di Gianvincenzo P, Enríquez-Navas PM, Martínez-Ávila OM, Chiodo F, Yuste E, *et al.* Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12. *J Mol Biol* 2011;**410**:798–810.
49. Adams EW, Ratner DM, Seeberger PH, Hacohen N. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. *Chembiochem Eur J Chem Biol* 2008;**9**:294–303.
50. Ahlén G, Strindeliu L, Johansson T, Nilsson A, Chatzissavidou N, Sjöblom M, *et al.* Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses. *PloS One* 2012;**7**:e46959.
51. Sheng K-C, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, *et al.* Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. *Immunology* 2006;**118**:372–83.



52. Ahmad S, Zamry AA, Tan H-TT, Wong KK, Lim J, Mohamud R. Targeting dendritic cells through gold nanoparticles: A review on the cellular uptake and subsequent immunological properties. *Mol Immunol* 2017;**91**:123–33.
53. Cruz LJ, Tacke PJ, Zeelenberg IS, Srinivas M, Bonetto F, Weigelin B, *et al.* Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism. *Mol Pharm* 2014;**11**:4299–313.
54. Quach QH, Kah JCY. Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials. *Nanotoxicology* 2017;**11**:382–94.
55. Silva JM, Zupancic E, Vandermeulen G, Oliveira VG, Salgado A, Videira M, *et al.* In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. *J Control Release Off J Control Release Soc* 2015;**198**:91–103.
56. Li S, Qi X, Gao Y, Hao Y, Cui L, Ruan L, *et al.* IL-15 increases the frequency of effector memory CD8<sup>+</sup> T cells in rhesus monkeys immunized with HIV vaccine. *Cell Mol Immunol* 2010;**7**:491–4.
57. Brincks EL, Woodland DL. Novel roles for IL-15 in T cell survival. *F1000 Biol Rep* 2010;**2**:67.
58. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8<sup>+</sup> T cells to sites of CD4<sup>+</sup> T cell-dendritic cell interaction. *Nature* 2006;**440**:890–5.
59. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. *J Leukoc Biol* 1997;**61**:246–57.
60. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. *Annu Rev Immunol* 2000;**18**:593–620.
61. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8<sup>+</sup> T cells. *Science* 1995;**270**:1811–5.
62. Lillard JW, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. *J Immunol Baltim Md 1950* 2001;**166**:162–9.
63. Athie-Morales V, Smits HH, Cantrell DA, Hilkens CMU. Sustained IL-12 signaling is required for Th1 development. *J Immunol Baltim Md 1950* 2004;**172**:61–9.
64. Foulds KE, Wu C, Seder RA. Th1 memory: implications for vaccine development. *Immunol Rev* 2006;**211**:58–66.

65. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, *et al.* Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. *Nat Commun* 2014;**5**:4092.
66. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. *Science* 1997;**277**:2005–7.
67. Nakayama T, Hirahara K, Onodera A, Endo Y, Hosokawa H, Shinoda K, *et al.* Th2 Cells in Health and Disease. *Annu Rev Immunol* 2016;
68. Di Gianvincenzo P, Chiodo F, Marradi M, Penadés S. Gold manno-glyconanoparticles for intervening in HIV gp120 carbohydrate-mediated processes. *Methods Enzymol* 2012;**509**:21–40.
69. Bernardi A, Jiménez-Barbero J, Casnati A, De Castro C, Darbre T, Fieschi F, *et al.* Multivalent glycoconjugates as anti-pathogenic agents. *Chem Soc Rev* 2013;**42**:4709–27.




Figure 1

ACCEPTED




Figure 2

ACCEPTED




Figure 3




Figure 4

ACCEPTED




Figure 5





Figure 6

ACCEPTED





### Graphical abstract

Schematic representation of *ex vivo* assays performed with formulations based on HLA-A\*0201-restricted HIV-peptides and Mannosides co-conjugated to GNPs (P1@HM). P1@HM interaction, process and antigen presentation by DC derived from blood monocytes of HIV+ individuals, promotes T-cell proliferation of autologous lymphocytes obtained from the same HLA-A\*0201 HIV-1<sup>+</sup> individuals. P1@HM treatment consistently enhances highly functional pro-T<sub>H</sub>1 cytokines, pro-T<sub>H</sub>1 chemokines, pro-inflammatory cytokine and several pro-T<sub>H</sub>2 cytokines as important immune factors that could potentiate a high adjuvant effect in an HIV vaccine context.